Mesoblast Limited (ASX:MSB) Insider Eric Rose Acquires 21,428 Shares of Stock

Mesoblast Limited (ASX:MSB) insider Eric Rose bought 21,428 shares of the firm’s stock in a transaction that occurred on Tuesday, April 30th. The shares were acquired at an average cost of A$6.64 ($4.40) per share, for a total transaction of A$142,324.78 ($94,254.82).

Mesoblast Price Performance

The company has a debt-to-equity ratio of 23.98, a current ratio of 2.71 and a quick ratio of 1.82.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.